Karakousis, Petros C. , Hafner, Richard , Gennaro, Maria Laura

Advances in Host-Directed Therapies Against Tuberculosis

Karakousis, Petros C. , Hafner, Richard , Gennaro, Maria Laura

Advances in Host-Directed Therapies Against Tuberculosis

Beschreibung Autorinnen & Autoren

This book discusses specific immune cell regulatory pathway(s), immune cell types, or other mechanisms involved in host responses to tuberculosis that can be potentially targeted for host-directed therapy (HDT). The pathways/mechanisms investigated are either protective - thus calling for pathway/factor enhancing drugs - or maladaptive - thus calling for pathway/factor inhibitory drugs. Discovery and development (pre-clinical and clinical) of candidate HDT agents will also be elucidated, as well as approaches for HDT of other diseases. The benefit to the reader will derive from learning about the biology of multiple host pathways involved in health and disease, how these pathways are disrupted or dysregulated during tuberculosis, and which druggable targets exist in these pathways. This book provides the reader with a roadmap of current and future directions of HDT against tuberculosis. Since the host pathways/factors involved in protective or maladaptive responses to tuberculosis are not disease-specific, information learned from the context of tuberculosis likely will be relevant to other infectious and non-infectious diseases.

Section 1: IntroductionChapter 1: Introduction: An overview of host-directed therapies for tuberculosisDaniel Frank, Robert Mahon Section 2: Targeting immunometabolism Chapter 2: Sirtuin deacetylases: Linking Mycobacterial infection and host metabolismLorissa Smulan, Hardy Kornfeld, and Amit SinghalChapter 3: The mammalian target of rapamycin complex 1 (mTORC1): an ally of M. tuberculosis in host cellsNatalie Bruiners, Valentina Guerrini, Maria Laura GennaroChapter 4: HIF-1 as a potential therapeutic target for tuberculosis treatment Qingkui Jiang, Maria Laura Gennaro, Lanbo ShiChapter 5: Nuclear receptors in host-directed therapies against tuberculosis Eun-Kyeong Jo Section 3: Enhancing anti-mycobacterial mechanismsChapter 6: Autophagy as a target for host-directed therapy against tuberculosis Surbhi Verma, Raman Deep Sharma and Dhiraj KumarChapter 7: Metformin: a leading HDT candidate for TB Amit Singhal and Hardy Kornfeld Chapter 8: Statins as host-directed therapy for tuberculosisNoton K. Dutta, Petros C. Karakousis Chapter 9: Antimycobacterial attributes of mitochondria: An insight into host defense mechanismsRikesh K Dubey, Apoorva Narain Section 4: Targeting immune cells Chapter 10: Conventional and unconventional lymphocytes in immunity against Mycobacterium tuberculosis Paula Ruibal, Tom H.M. Ottenhoff, Simone A. JoostenChapter 11: Targeting inhibitory cells such as Tregs and MDSCs in the tuberculous granulomaSadiya Parveen, John R. Murphy, and William R. BishaiChapter 12: Targeting suppressor T cells Léanie Kleynhans, Gerhard WalzlChapter 13: Neutrophil-mediated mechanisms as targets for host-directed therapies against tuberculosis Tobias Dallenga, Ulrich E. SchaibleChapter 14: Type I interferon and interleukin-1 driven inflammatory pathways as targets for HDT in tuberculosisKatrin D. Mayer-Barber, Christopher M. SassettiChapter 15: Mucosal-associated invariant and VGamma9Vd2 T cellsCharles K. Vorkas, Michael S. GlickmanChapter 16: Airway epithelial cellsAngélica M. Olmo-Fontánez, Jordi B. Torrelles Section 5: Preclinical models for assessing HDTsChapter 17: In vitro models of human granuloma formation to analyze host-directed therapiesLiku B. Tezera, Michaela T. Reichmann, Basim Al Shammari, Paul T. ElkingtonChapter 18: C3HeB/FeJ as a key mouse strain for testing host-directed therapies against tuberculosisPere-Joan Cardona, Cristina VilaplanaChapter 19: The Rabbit Model for Assessing Host-Directed Therapies for Tuberculosis Selvakumar Subbian, Gilla Kaplan Section 6: Clinical trials of HDTs and special considerations for study endpointsChapter 20: Clinical trials of TB-HDT candidatesRobert S. WallisChapter 21: Outcomes for clinical trials of host-directed therapies for tuberculosis Akshay N. Gupte, Sara C. Auld, William N. Checkley, Gregory P. BissonChapter 22: Pharmacological considerations for clinical trials of host-directed therapies for tuberculosis Elisa H. Ignatius, Kelly E. Dooley

ISBN	978-3-030-56904-4
Artikelnummer	9783030569044
Medientyp	Buch
Auflage	1st ed. 2021
Copyrightjahr	2020
Verlag	Springer, Berlin
Umfang	XIII, 332 Seiten
Abbildungen	XIII, 332 p. 20 illus.
Sprache	Englisch